Taken together, our findings argue strongly for a morphometric component in future studies in humans and in sclerosteosis patients, and argue as well for the potential importance of studying long‐term effects of sclerostin antibody treatment in the mouse model, specifically, its effects on malformations, mandibular prognathism, and nerve entrapment. This evidence concerns the gene SOST and sclerosteosis.